The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

Recent studies have shown that both the quality and the amount of sleep we get may influence our risk of developing Alzheimer ...

INDICATION LEQEMBI ® [ (lecanemab-irmb) 100 mg/mL injection for intravenous use] is indicated for the treatment of Alzheimer’s disease (AD). Treatment with LEQEMBI should be initiated in patients with ...

The likelihood of being diagnosed with dementia is more than six times higher in people aged 80 and over compared to those aged 65-79. Not everyone develops the condition as they age. Changes in the ...

Preserving levels of brain glucose metabolism can both slow cognitive decline and reduces the risk of conversion to dementia.

LATE is a prevalent condition in late life and can contribute to memory loss and cognitive decline, according to report ...

New guidelines will help doctors identify patients with a common memory-loss syndrome that is often misdiagnosed as Alzheimer's disease in older adults. The diagnostic criteria for limbic-predominant ...

The lack of proper blood flow deprives brain cells of oxygen and nutrients, leading to damage or death of brain tissue.

New guidelines will help doctors identify patients with a common memory-loss syndrome that is often misdiagnosed as Alzheimer's disease in older adults.

Aerobic Exercise (Cardio): Physical activities like walking, running, swimming and cycling boost oxygen levels in the brain, ...

Eisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...

A study led by scientists at Rutgers University-New Brunswick has shown that specialized cells involved in how the body ...